Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, dated August 11, 2025, reports a transaction in own shares. Haleon is a global leader in consumer health with a portfolio spanning Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health.
Key Financial Metrics and Transaction Details
The filing details a share buyback transaction executed on August 8, 2025, under the second tranche of a programme announced on July 31, 2025. The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures.
| Metric | Value |
|---|---|
| Shares Purchased | 856,760 |
| Purpose | Cancellation |
| Highest Price Paid | 356.10 pence |
| Lowest Price Paid | 353.50 pence |
| Volume Weighted Average Price | 354.62 pence |
| Registered Share Capital Post-Transaction | 8,979,735,788 ordinary shares |
| Treasury Shares Held | 3,880,205 |
| Voting Shares Outstanding | 8,975,855,583 |
Material Changes
The primary material change is the reduction of the company's share count due to the cancellation of 856,760 shares. Consequently, the number of ordinary shares with voting rights is now 8,975,855,583. No other financial or operational changes are reported in this specific filing.
Guidance, Outlook, and Risks
This filing contains no forward-looking guidance, management commentary on future performance, or discussion of risks and contingencies. It is a regulatory disclosure of a completed share repurchase transaction.
Key Facts for Investor Verification
- Verify the total remaining authorization under the share buyback programme announced on July 31, 2025.
- Confirm the impact of the share cancellation on earnings per share (EPS) in upcoming financial reports.
- Review the full trade breakdown available via the London Stock Exchange link provided in the filing for granular execution data.
- Monitor the company's website for updates on the completion of the second tranche of the buyback programme.